R
Robert J. Lupinacci
Researcher at Merck & Co.
Publications - 29
Citations - 2855
Robert J. Lupinacci is an academic researcher from Merck & Co.. The author has contributed to research in topics: Medicine & Caspofungin. The author has an hindex of 12, co-authored 17 publications receiving 2730 citations. Previous affiliations of Robert J. Lupinacci include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Jorge Mora-Duarte,Robert F. Betts,Coleman Rotstein,Arnaldo Lopes Colombo,Luis Thompson-Moya,Juanita M Smietana,Robert J. Lupinacci,Carole A. Sable,Nicholas A. Kartsonis,John R. Perfect +9 more
TL;DR: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Journal ArticleDOI
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J. Walsh,Hedy Teppler,Gerald R. Donowitz,Johan Maertens,Lindsey R. Baden,Anna Dmoszynska,Oliver A. Cornely,Michael R. Bourque,Robert J. Lupinacci,Carole A. Sable,Ben E. dePauw +10 more
TL;DR: Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Journal ArticleDOI
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
Alvaro Villanueva,Eduardo Gotuzzo,Eduardo G. Arathoon,L. Miguel Noriega,Nicholas A. Kartsonis,Robert J. Lupinacci,Juanita M Smietana,Mark J. DiNubile,Carole A. Sable +8 more
TL;DR: Caspofungin appeared to be as efficacious and generally as well tolerated as fluconazole in patients with advanced HIV infection and documented Candida esophagitis in this study.
Journal ArticleDOI
Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Arnaldo Lopes Colombo,John R. Perfect,Mark J. DiNubile,K. Bartizal,Mary Motyl,P. Hicks,Robert J. Lupinacci,Carole A. Sable,Nicholas A. Kartsonis +8 more
TL;DR: Outcomes were comparable for patients treated with caspofungin and amphotericin B and were generally similar across continents, and may affect the regional choice of empirical antifungal therapy for seriously ill patients with suspected or documented invasive candidiasis since different Candida species have varying susceptibility to conventional antIFungal drugs.
Journal ArticleDOI
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Mikhail Lichinitser,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Robert J. Lupinacci,Clemens Krepler,Nageatte Ibrahim,Michal Kicinski,Sandrine Marreaud,Alexander C.J. van Akkooi,Stefan Suciu,Caroline Robert +31 more
TL;DR: AJC-8 staging had a strong prognostic importance for RFS but no predictive importance: the RFS benefit of pembrolizumab was observed across AJCC-8 subgroups in resected high-risk stage III melanoma patients.